Addressing a press conference, V K Paul, member (health), NITI Aayog, said studies are going on regarding the mixing and matching of booster doses of COVID-19 vaccines and they are being “constantly reviewed”
The government recently said that any decision on the mixing and matching of booster dose of COVID-19 vaccines will be taken based on science.
Addressing a press conference, Dr V K Paul, member (health), NITI Aayog, said studies are going on regarding the mixing and matching of booster doses of COVID-19 vaccines and they are being “constantly reviewed.”
As per the new information and science and knowledge, a decision would be guided on (by) that,” he said.
On the Corbevax vaccine, Paul said it will find a way into the national vaccination programme as an order has been placed and delivered for a certain quantity.
A decision on how and when to use it will be based on scientific considerations.
“As the Emergency Use Authorisation (EUA) (for Corbevax) has been given for general adult population and also for children, be rest assured that the data has been seen by the drug regulator (before giving the nod).”
“We have placed the order for a certain quantum which has been delivered. This vaccine will find a way in(to) the national programme but how best to use it and when to use it, these decisions will follow based on scientific considerations and the overall approach of our vaccination programme which focusses on systematic approach starting with the most needy and high prioritised groups,” Paul said.
The Corbevax vaccine is administered through intramuscular route with two doses scheduled 28 days apart.
It is stored at two-to-eight degrees Celsius and presented as 0.5 ml (single dose) and 5 ml (10 doses) vial pack.
Responding to a query on whether COVID-19 vaccination will be an annual affair, Balram Bhargava, Director-General, Indian Council for Medical Research (ICMR), said the jury is out on that.
“We have seen that for influenza, a yearly vaccination has been found to be useful. It is being practised for high-risk groups in India. We don’t know whether this disease has become endemic or is becoming endemic. Once that happens, we will be in a better position to answer,” he said.